Regeneron Acquires 23andMe Assets for $256M to Expand Consumer Genomics and Data-Driven Drug Discovery
Regeneron has announced an agreement to acquire substantially all assets of 23andMe for $256 million, following a bankruptcy auction process. The transaction, expected to close in Q3 2025 pending court and regulatory approvals, would include 23andMe’s Personal Genome Service, Total Health platform, and research services—along with its biobank and other associated assets. Notably, the deal does not include Lemonaid Health.
If approved, 23andMe would continue operations as a wholly owned subsidiary of Regeneron Pharmaceuticals, maintaining its consumer-facing genetic testing services. According to Regeneron, the acquisition is intended to both preserve 23andMe’s direct-to-consumer business and integrate its genomic assets into Regeneron’s broader genetics-guided drug development strategy.
See also: 23andMe Files for Bankruptcy
This move comes at a time when Regeneron is emphasizing scale in human genetics. Through its Genetics Center, the company has reportedly sequenced more than 2.7 million exomes, combining deidentified genomic data with EHRs for target discovery and validation. The 23andMe acquisition would bring in one of the most widely recognized consumer datasets in genomics built over more than a decade and create potential for new research pipelines, pending ethical, legal, and consent considerations.
Regeneron has pledged to uphold 23andMe’s existing privacy policies and work with a court-appointed Customer Privacy Ombudsman to ensure compliance and transparency. In statements, company executives framed the acquisition as an opportunity to responsibly unlock further value from large-scale genetic data while maintaining high standards for security and ethical oversight.
Topics: Startups & Deals
